

QUALITY POLICY AND QUALITY OBJECTIVES

As of 2022, following major management and organizational changes in AIRC and IFOM, Cogentech Srl Società Benefit has been even more committed to supporting AIRC's mission by providing AIRC-funded researchers with innovative and quality technology services.

Cogentech's management is committed to defining, as a Quality Policy, the company's Mission, which can be summarized as follows:

- The performance, on its own account and on behalf of third parties, of research and development activities in the field of molecular medicine and diagnostics for the purpose of developing and producing new diagnostic, predictive and prognostic tests in the field of human medicine, particularly in oncology and diseases associated with aging, as well as in veterinary medicine.
- The research and development and laboratory activity of germline and somatic genetic analysis (performance of diagnostic tests) on its own account and on behalf of third parties.
- In the field of diagnostics, Cogentech is committed to the further development of innovative models built on the needs of the Client, which ensure more effective prevention and better protection of the health of the person.
- The management of devices for "In House Tests" in accordance with EU Regulation EU 746/2017 within a Health Institution ("Health Institution").
- The management of Service activities and technical support to Research, through the promotion, management and coordination of technology platforms specific to the biomedical and informatics sector.
- The provision to the member and third parties of Services and access to assets, machinery, and facilities in connection with the activity described above.
- The registration, purchase and sale of patents, licenses, trademarks and concessions pertaining to the company's business.

CGT Lab and IGU Laboratories, both Medical Genetics Specialty Laboratory Services with Molecular Genetics area of Cogentech, conducts its activities following the principles of **impartiality** and non-discrimination, respecting the rights of patients, not allowing this value to be compromised for any reason.

The laboratories assures its clients about the availability and integrity of specimens and records in the event of closure, acquisition, or merger of the laboratory.

The laboratories also commits to operate in accordance with EU REG. No. 2016/679 of the European Parliament and of the Council of April 27, 2016, to ensure communication to the user in case of release of mandatory notification information, and to ensure confidentiality of sources regarding information received about users.

The Management of Cogentech is aware that achieving the set objectives requires analyzing the context in which it operates, the needs of stakeholders and the risks associated with its activities. As a result, we regularly assess these factors with the help of our management team, identifying the most suitable actions for improvement.

The quality management system is constantly implemented, updated and improved through appropriate internal communication actions. Operators are aware of the importance of their activities and how everyone's contribution can enable Cogentech to achieve the quality and continuous improvement goals it has set for itself.

Cogentech establishes in this Policy its objectives for quality. In order to keep its achievement monitored, the company has identified specific indicators both at the general level and for each individual facility. All performance indicators are monitored and updated periodically. Achievement of the objectives is also analyzed in the management review.


Cogentech also aims to contribute to the scientific debate in an increasingly active and concrete way through publications in international journals, participation in institutional programs on quality control of genetic testing, and collaboration in the drafting of industry guidelines.

Management is committed to ensuring that this Policy is disseminated, understood and implemented at all levels of the Organization.

Date 18.04.2025

The Management of

Cogentech srl SB

A handwritten signature in black ink, written over a horizontal line. The signature is stylized and appears to be 'G. Di'.